Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 26
Filter
1.
Lupus ; 19(2): 138-45, 2010 Feb.
Article in English | MEDLINE | ID: mdl-19952070

ABSTRACT

This study was designed to investigate whether Foxp3( +) regulatory T (Treg) cells play a role in the histopathologic changes of primary Sjögren's Syndrome (pSS) and to evaluate other factors possibly associated with Foxp3(+) Treg cells in pSS patients. The number of FoxP3-expressing T cells in peripheral blood (PB) of 39 patients with pSS, 40 patients with rheumatoid arthritis (RA), and 28 healthy controls was measured by flow-cytometer analysis. FoxP3-expressing CD4(+)CD25(+) Treg cells were analyzed in minor salivary gland (SG) tissues of 39 pSS patients. Histopathologic changes were examined by light microscopy according to Chisholm's classification. Immunohistochemistry and immunofluorescence were performed to assess the Foxp3(+) Treg in SG biopsy specim-ens. The numbers of CD4(+) T cells and FoxP3-expressing CD4(+) T cells in PB were similar in all groups. Expression of CD25 on CD4(+) T cells in PB of patients with pSS and RA was significantly higher than in healthy controls, especially for RA patients. Immunohistochemistry and immunofluorescence showed that FoxP3(+) Treg were enriched in the SGs of pSS patients, with a positive correlation between the increase in FoxP3(+) Treg in SG and the Chisholm score in pSS (p < 0.001, r = +0.605). The increase of FoxP3( +) Treg cells in the SGs of pSS patients, which is correlated with gland infiltration, suggests that natural regulatory T cells play an important role in the pathogenesis of pSS. Further studies are required to explore the mechanisms that mediate the relationship between Treg and the pathogenesis of pSS.


Subject(s)
Forkhead Transcription Factors/metabolism , Salivary Glands/immunology , Sjogren's Syndrome/pathology , T-Lymphocytes, Regulatory/immunology , Adult , Aged , Arthritis, Rheumatoid/immunology , Case-Control Studies , Cell Movement , Female , Flow Cytometry , Fluorescent Antibody Technique , Humans , Male , Middle Aged , Salivary Glands/pathology , Sjogren's Syndrome/immunology , Young Adult
2.
Lupus ; 19(3): 255-61, 2010 Mar.
Article in English | MEDLINE | ID: mdl-20015916

ABSTRACT

Neurological involvement is a well-documented issue in patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). However, little is known about the involvement of the autonomic nervous system. This study was conducted to investigate autonomic nervous system dysfunction in patients with RA and SLE. Twenty-six RA patients, 38 SLE patients and 40 healthy controls were recruited from our in- and out-patient departments. Heart rate variability (HRV) parameters (the power of the high- [HF] and low-frequency [LF] band of haemodynamic time series, the ratio between low- and high-frequency components [LF/HF ratio], the power spectral density), baroreflex sensitivity (BRS) and beat-to-beat blood pressures were assessed by a novel non-invasive haemodynamic monitoring tool (Task Force Monitor [TFM], CNSystems Medizintechnik GmbH, Graz, Austria). Autonomic nervous system dysfunction was determined according to classical Ewing autonomic test battery. Furthermore, we implemented a secondary autonomic test score by modifying the Ewing test battery with additional criteria. Both the classical and modified Ewing test batteries have revealed that the frequencies of autonomic neuropathy were significantly higher in patient groups compared with controls (p < 0.001). Evaluation by TFM revealed that deterioration of sophisticated autonomic parameters (such as HRV and BRS) were more pronounced in the patient groups compared with controls. There was a significant association between BRS and Ewing test scores and abnormal BRS results were more frequent in patients with autonomic dysfunction according to Ewing test batteries. No relation was found between autonomic neuropathy and disease duration, disease activity and autoantibody positivity. Consequently, we believe that further large-scale studies investigating cardiovascular autonomic neuropathy in rheumatic diseases should be carried out to verify our findings and manifest clinical consequences beyond these results.


Subject(s)
Arthritis, Rheumatoid/complications , Autonomic Nervous System Diseases/etiology , Cardiovascular Diseases/etiology , Lupus Erythematosus, Systemic/complications , Adult , Aged , Autonomic Nervous System Diseases/epidemiology , Baroreflex , Blood Pressure , Cardiovascular Diseases/epidemiology , Case-Control Studies , Female , Heart Rate , Humans , Male , Middle Aged
3.
Lupus ; 19(3): 323-6, 2010 Mar.
Article in English | MEDLINE | ID: mdl-20007815

ABSTRACT

Systemic lupus erythematosus (SLE) is a disease with wide range of signs and symptoms. SLE patients have increased infective diathesis, and infections are a very important cause of death in these patients. Infections can sometimes mimic the signs and symptoms of SLE. Thus, it is important to recognize that infection can induce a lupus flare-up or can be difficult to distinguish from a lupus flare-up. We describe a 36-year-old female patient with SLE, who presented with skin lesions and pancytopenia, and clinical manifestations similar to a flare-up of SLE. Bone marrow examination revealed infection with Mycobacterium avium complex (MAC). The patient had no history or clinical evidence of pulmonary involvement. This patient is the first case of invasive bone marrow MAC infection in SLE. With this unique case, we would like to emphasize that SLE patients can also be infected by non-tuberculous mycobacteria, and that bone marrow examination for tuberculosis as well as for non-tuberculosis mycobacteria should be considered in SLE patients with refractory pancytopenia.


Subject(s)
Bone Marrow Diseases/microbiology , Lupus Erythematosus, Systemic/complications , Mycobacterium avium-intracellulare Infection/complications , Adult , Bone Marrow Diseases/physiopathology , Female , Humans , Lupus Erythematosus, Systemic/physiopathology , Mycobacterium avium Complex/isolation & purification , Mycobacterium avium-intracellulare Infection/physiopathology , Pancytopenia/etiology , Pancytopenia/microbiology
4.
Int J Clin Pract ; 64(1): 19-24, 2010 Jan.
Article in English | MEDLINE | ID: mdl-18284438

ABSTRACT

BACKGROUND: Propylthiouracil (PTU) is the mainstay of antithyroid drug therapy. Previous studies reported antineutrophil cytoplasmic antibody (ANCA)-positive vasculitis in patients treated for Graves' disease. ANCA has been associated with either PTU or to the disease itself. However, this issue has not been investigated in toxic multinodular goitre (TMNG). The aim of this study was to evaluate the frequency of ANCA positivity in both TMNG and Graves' disease patients treated with PTU, and to investigate the clinical importance of this issue. PATIENTS AND METHODS: We studied the presence of ANCA in 46 patients treated with PTU (30 Graves' disease, 16 TMNG). Two years after the discontinuation of PTU, ANCA was re-evaluated in 29 patients (18 Graves' disease, 11 TMNG). RESULTS: By indirect immunofluorescence, 19 of the 46 patients (41.3%) on PTU treatment were ANCA positive [13 of the 30 patients in Graves disease (43.3%), six of the 16 patients in TMNG (37.5%)]. There was no statistically significant difference between Graves' disease and TMNG patients for ANCA positivity (p = 0.362). ANCA positivity was not related to gender, thyroid autoantibodies, alanine aminotransferase, aspartate aminotransferase, neutrophil count and PTU dose. Two years after withdrawal of PTU treatment, 10.3% of patients continued to have positive ANCA (p < 0.0001). Signs and symptoms of vasculitis could not be detected in any of the ANCA-positive patients. CONCLUSION: Our study suggests that PTU but not Graves' disease itself is the most important factor for ANCA development. The frequency of ANCA positivity is 41.3% in our country which was not different in Graves' disease and TMNG patients. The dose of PTU and ethnic factors are not associated with ANCA positivity. After cessation of PTU, vasculitis did not develop during the 2 years of follow-up despite positive ANCA.


Subject(s)
Antibodies, Antineutrophil Cytoplasmic/metabolism , Antithyroid Agents/therapeutic use , Graves Disease/drug therapy , Propylthiouracil/therapeutic use , Adult , Aged , Female , Graves Disease/immunology , Humans , Male , Middle Aged , Thyroid Function Tests , Young Adult
5.
Int J Immunogenet ; 36(4): 245-50, 2009 Aug.
Article in English | MEDLINE | ID: mdl-19602000

ABSTRACT

Cytotoxic T lymphocyte-associated antigen-4 is a cell-surface molecule providing a negative signal for T cell activation. CTLA-4 gene polymorphisms are known to be related with genetic susceptibility to various autoimmune diseases, including systemic lupus erythematosus (SLE). However, the effects of this polymorphism on clinical features of SLE have not been defined. We analysed the CTLA-4 gene +49 A/G polymorphisms in patients with SLE by using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) and investigated the effect of polymorphisms on clinical outcomes. Blood was collected from 47 unrelated Turkish SLE patients, all fulfilling the American College of Rheumatology criteria for SLE, and 100 ethnically matched healthy volunteers. The AA genotype was a predominant genotype in the Turkish population and genotype frequencies of CTLA-4 AA were significantly higher in SLE patients (70%) than healthy controls (47%) (P = 0.015). There was a statistically significant difference in the AA genotype [odds ratio (OR): 2.66, confidence interval (CI) 95%: 1.27-5.56, P = 0.014] distribution among patients and controls. There was also an increase in A allele frequency in SLE and controls, but the difference was not statistically significant (81% vs. 70%, P = 0.068, OR = 1.8, CI 95%: 0.99-3.28). Interestingly, mean age and mean age of onset disease was higher in AA homozygote SLE patients compared to non-AA (39.2 +/- 11.5 vs. 31.6 +/- 10.6, P = 0.044; 32.38 vs. 24.31, P = 0.046, respectively). There was no association between genotype and the other clinical features of SLE. Our results suggested that CTLA-4 +49 AA genotype might be a risk factor for the development of SLE in Turkish population and G allele might be involved in early development of SLE. No association with clinical features was found for polymorphism of the promoter region in CTLA-4 +49.


Subject(s)
Antigens, CD/genetics , Gene Frequency/genetics , Lupus Erythematosus, Systemic/genetics , Adult , Alleles , Antigens, CD/immunology , CTLA-4 Antigen , Exons/genetics , Exons/immunology , Female , Gene Frequency/immunology , Genetic Predisposition to Disease , Genotype , Humans , Lupus Erythematosus, Systemic/immunology , Male , Middle Aged , Polymorphism, Single Nucleotide/genetics , Polymorphism, Single Nucleotide/immunology , Promoter Regions, Genetic , Turkey
6.
Immunol Lett ; 124(1): 44-9, 2009 May 14.
Article in English | MEDLINE | ID: mdl-19379773

ABSTRACT

Previous studies showed a fetal sheep liver extract (FSLE), in association with monophosphoryl lipid A, MPLA (a bioactive component of lipid A of LPS), could interact to induce the development of dendritic cells (DCs) which regulated production of Foxp3+ Treg. This interaction was associated with an altered gene expression both of distinct subsets of TLRs and of CD200Rs. Prior studies had suggested that major interacting components within FSLE were gamma-chain of fetal hemoglobin (Hgbgamma) and glutathione (GSH). We investigated whether differentiation/maturation of DCs in vitro in the presence of either GM-CSF or Flt3L to produce preferentially either immunogenic or tolerogenic DCs was itself controlled by an interaction between MPLA, GSH and Hgbgamma. At low (approximately 10 microg/ml) Hgbgamma concentrations, DCs developing in culture with GSH and MPLA produced optimal stimulation of allogeneic CTL cell responses in vitro (and enhanced skin graft rejection in vivo). At higher concentrations (>40 microg/ml Hgbgamma) and equivalent concentrations of MPLA and GSH, the DCs induce populations of Treg which can suppress the induction of allogeneic CTL and graft rejection in vivo. These different populations of DCs express different patterns of mRNAs for the CD200R family. Addition of anti-TLR or anti-MD-1 mAbs to DCs developing in this mixture (Hgbgamma+GSH+MPLA), suggests that one effect of (GSH+Hgbgamma) on MPLA stimulation may involve altered signaling through TLR4.


Subject(s)
Dendritic Cells/metabolism , Fetal Hemoglobin/metabolism , Glutathione/metabolism , Graft Rejection/immunology , Lipid A/analogs & derivatives , T-Lymphocytes, Regulatory/metabolism , Animals , Antibodies, Blocking , Bone Marrow/pathology , Cell Differentiation , Dendritic Cells/immunology , Dendritic Cells/pathology , Fetal Hemoglobin/immunology , Glutathione/immunology , Graft Rejection/blood , Graft Rejection/pathology , Graft Rejection/prevention & control , Granulocyte-Macrophage Colony-Stimulating Factor/immunology , Granulocyte-Macrophage Colony-Stimulating Factor/metabolism , Histocompatibility Antigens , Immune Tolerance , Immunity, Cellular , Lipid A/immunology , Lipid A/metabolism , Membrane Glycoproteins/genetics , Membrane Glycoproteins/immunology , Membrane Glycoproteins/metabolism , Membrane Proteins/immunology , Membrane Proteins/metabolism , Mice , Mice, Inbred C3H , Mice, Inbred C57BL , Mice, Knockout , Signal Transduction , Skin Transplantation , T-Lymphocytes, Cytotoxic/immunology , T-Lymphocytes, Cytotoxic/metabolism , T-Lymphocytes, Cytotoxic/pathology , T-Lymphocytes, Regulatory/immunology , T-Lymphocytes, Regulatory/pathology , Toll-Like Receptor 4/genetics , Toll-Like Receptor 4/immunology , Toll-Like Receptor 4/metabolism
7.
Colorectal Dis ; 10(9): 953-4, 2008 Nov.
Article in English | MEDLINE | ID: mdl-18294265

ABSTRACT

Inhibition of tumour necrosis factor (TNF)-alpha is effective in the treatment of rheumatoid arthritis and other inflammatory rheumatic diseases. Anti-TNF antibodies such as infliximab, etanercept and adalimumab are commonly used. There are structural and functional differences among these agents. We describe development of Crohn's disease in a patient with ankylosing spondylitis receiving anti-TNF therapy. This case suggests that the appearance of gastrointestinal symptoms in patients on anti-TNF therapy must be evaluated to find out whether this is a new onset or an exacerbation of underlying inflammatory bowel disease.


Subject(s)
Crohn Disease/chemically induced , Immunoglobulin G/adverse effects , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Antibodies, Monoclonal/pharmacology , Crohn Disease/diagnosis , Crohn Disease/immunology , Etanercept , Humans , Immunoglobulin G/pharmacology , Immunoglobulin G/therapeutic use , Infliximab , Male , Receptors, Tumor Necrosis Factor/therapeutic use , Spondylitis, Ankylosing/epidemiology , Spondylitis, Ankylosing/immunology , Young Adult
8.
Lupus ; 16(12): 993-6, 2007.
Article in English | MEDLINE | ID: mdl-18042595

ABSTRACT

Alternaria species are common saprophytic fungi that naturally subsist on decaying plant materials, and occasionally may cause diseases in human beings and domestic animals. They can be a potential opportunistic pathogen in immunocompromized hosts or those with significant underlying disease. However, rarely they are also pathogen in otherwise healthy hosts. We report here the first case of cutaneous alternariosis in a 30-year-old woman who was on systemic steroid therapy for active systemic lupus erythematosus. The patient was referred to our department with purple papules and ulcerated nodules on the dorsum of the hands, wrists and ankles. Skin biopsy showed granulomatous reaction with fungal elements that were subsequently identified as Alternaria species. Individual lesions were successfully treated with oral itracanozole 200mg daily for six weeks. Besides the patient's own disease, the use of systemic steroid use might be a possible predisposing factor for the development of cutaneous alternariosis.


Subject(s)
Alternaria/pathogenicity , Dermatomycoses/etiology , Lupus Erythematosus, Systemic/complications , Adrenal Cortex Hormones/adverse effects , Adrenal Cortex Hormones/therapeutic use , Adult , Alternaria/drug effects , Antifungal Agents/therapeutic use , Dermatomycoses/drug therapy , Female , Humans , Immunocompromised Host , Itraconazole/therapeutic use , Lupus Erythematosus, Systemic/drug therapy
9.
Rheumatology (Oxford) ; 46(5): 783-9, 2007 May.
Article in English | MEDLINE | ID: mdl-17309888

ABSTRACT

Objectives. Rheumatoid arthritis (RA) is characterized by the chronic inflammation of the synovial joints resulting from the hyperplasia of synovial cells and the infiltration of lymphocytes, macrophages and plasma cells. Currently, the aetiology of RA is not known, and new treatment modalities are needed to prevent the disease progression. Apoptosis induction of synovial cells through the use of death ligands has been explored as a treatment modality for RA. Thus, the primary objective of this study was the testing of the efficacy of adenovirus delivery of human TRAIL (Ad5hTRAIL) for the treatment of patients with RA. Methods. Primary synovial cell cultures were established from eight patients with RA. Adenovirus permissiveness of synovial cells was determined by the infection of synoviocytes with adenovirus vector encoding green fluorescent protein (AdEGFP). TRAIL sensitivity of synoviocytes was assessed through the infection with Ad5hTRAIL vector using Live/Death Cellular Viability/Toxicity kit from Molecular Probe. TRAIL receptor profiles of synoviocytes were revealed by real-time RT-PCR assays followed by flow cytometric analyses. Results. While the presence of TRAIL death receptors were necessary for the induction of cell death, high levels of TRAIL-R4 decoy receptor expression on surface were correlated with TRAIL resistance. A DcR2 siRNA approach in combination with Ad5hTRAIL infection eliminated apoptosis-resistant RA synovial fibroblasts. Conclusion. Because a DcR2 siRNA approach in combination with Ad5hTRAIL infection exterminated RA synoviocytes to a greater extent than Ad5hTRAIL alone, the modulation of TRAIL receptor expression might be a new gene therapy strategy to sensitize RA synoviocytes to TRAIL.


Subject(s)
Arthritis, Rheumatoid/therapy , Genetic Therapy/methods , Receptors, TNF-Related Apoptosis-Inducing Ligand/genetics , Synovial Membrane/pathology , Arthritis, Rheumatoid/metabolism , Arthritis, Rheumatoid/pathology , Cell Death , Cells, Cultured , Down-Regulation , Genetic Vectors , Humans , RNA, Small Interfering/genetics , Receptors, TNF-Related Apoptosis-Inducing Ligand/metabolism , Reverse Transcriptase Polymerase Chain Reaction/methods , Transduction, Genetic
10.
Immunol Lett ; 105(2): 140-9, 2006 Jun 15.
Article in English | MEDLINE | ID: mdl-16540177

ABSTRACT

Previous reports from our group have established that the fetal ovine gamma globin chain (Hbgamma) and LPS can synergize in the induction of pro-inflammatory cytokines, especially TNFalpha, from mouse and human leukocytes. A fetal sheep liver extract (FSLE) which was observed to have marked immunoregulatory properties in vivo and in vitro had independently been observed to contain significant amounts of each of these molecules. However, the biological activity of this extract (hereafter FSLE) was not explained solely by its content of Hbgamma and LPS, and independent analysis confirmed also the presence of migration inhibitory factor, MIF, and glutathione in FSLE. We have investigated whether MIF and the cellular anti-oxidant glutathione can further synergize with Hbgamma and LPS in TNFalpha induction from human cells in vitro, and mouse cells activated in vivo/in vitro. Our data show that indeed there is evidence for such a synergy. Treatment or mouse cells with FSLE produced an enhanced TNFalpha production which could be inhibited independently both by anti-Hbgamma and by anti-MIF, and optimally by a combination of these reagents.


Subject(s)
Aging/physiology , Glutathione/pharmacology , Hemoglobins/metabolism , Leukocytes/drug effects , Lipopolysaccharides/pharmacology , Macrophage Migration-Inhibitory Factors/pharmacology , Recombinant Proteins/pharmacology , Tumor Necrosis Factor-alpha/biosynthesis , Animals , Cell Extracts/chemistry , Cell Extracts/pharmacology , Cell Polarity , Cells, Cultured , Fetal Blood/metabolism , Health , Heme/metabolism , Hemoglobins/isolation & purification , Humans , Leukocytes/metabolism , Liver/cytology , Liver/metabolism , Macrophage Migration-Inhibitory Factors/immunology , Mice , Mice, Inbred C57BL , Recombinant Proteins/immunology , Sheep
11.
Article in English | MEDLINE | ID: mdl-11436971

ABSTRACT

It is known that several inflammatory cells and cytokines play a role in allergic inflammation. Furthermore, there are seasonal changes in several mediators responsible for allergic inflammation. The aim of this study was to determine seasonal changes in serum concentrations of soluble tumor necrosis factor receptors (sTNFRs) and the relationship with disease activity and other inflammation markers such as eosinophil cationic protein (ECP) in patients with seasonal allergic rhinitis. Serum levels of sTNFRI and sTNFRII were measured before and during the pollen season in 18 patients with seasonal allergic rhinitis and in 17 healthy controls by using commercially available enzyme-linked immunosorbent assay (ELISA) kits. The serum levels of sTNFRI, sTNFRII, IgE, and ECP were significantly higher in patients than those in controls before and during season. sTNFRI, sTNFRII, and IgE levels were higher before season, whereas ECP levels were higher during season. We suggest that sTNFRs might play regulatory roles even in early stages of allergic rhinitis when patients do not have clinical symptoms yet.


Subject(s)
Receptors, Tumor Necrosis Factor/blood , Rhinitis, Allergic, Seasonal/blood , Ribonucleases , Adolescent , Adult , Aged , Blood Proteins/analysis , Eosinophil Granule Proteins , Female , Humans , Immunoglobulin E/blood , Male , Seasons
12.
J Nephrol ; 14(3): 184-9, 2001.
Article in English | MEDLINE | ID: mdl-11439742

ABSTRACT

BACKGROUND: Chronic peritoneal dialysis may eventually result in peritoneal fibrosis, which progressively reduces dialytic efficacy. Although the pathogenesis has not been elucidated, it has been proposed that transforming growth factor beta-1 (TGF beta 1) plays a central role in the onset of peritoneal fibrosis. METHODS: Rats were divided into three groups and given saline, hypertonic peritoneal dialysis solution alone, a hypertonic peritoneal dialysis solution plus octreotide intraperitoneally. After four weeks, a one-hour peritoneal equilibration test was done. Dialysate-to-plasma urea ratio, glucose reabsorption, ultrafiltration volume and levels of dialysate protein, TGF beta 1 and cancer antigen 125 (CA 125) were determined. The peritoneal membrane was examined histologically by light microscopy. RESULTS: Compared to the saline group, peritoneal function tests (ultrafiltration volume 6 (5-7) vs 0.0 ml, dialysate-to-plasma urea ratio 0.51 vs 0.76, glucose reabsorption 0.54 vs 0.40 and morphology (thickness 4.5 vs 75.5 microns) were dramatically deranged in hypertonic peritoneal dialysis solution-treated rats, which also had a higher level of TGF beta 1 and undetectable CA 125. In contrast, in hypertonic peritoneal dialysis solution plus octreotide rats' peritoneal function was protected (ultrafiltration volume 3 mL, dialysate-to-plasma urea 0.60, glucose reabsorption 0.51) but peritoneal thickening (37.7 microns) was not so markedly reduced although the production of TGF beta 1 was significantly inhibited. CONCLUSION: These data show that by inhibiting the production of TGF beta 1, octreotide can preserve peritoneal function and remodeling of the mesothelial cell. Although the production of TGF beta 1 was significantly inhibited, peritoneal thickening cannot be completely prevented.


Subject(s)
Glucose/administration & dosage , Octreotide/therapeutic use , Peritoneum/metabolism , Transforming Growth Factor beta/metabolism , Animals , Male , Rats , Rats, Wistar , Solutions , Transforming Growth Factor beta1
13.
Perit Dial Int ; 21(2): 219-24, 2001.
Article in English | MEDLINE | ID: mdl-11330572

ABSTRACT

OBJECTIVE: Peritoneal fibrosis (PF) is one of the most serious causes of failure in continuous ambulatory peritoneal dialysis (PD). Although the underlying mechanism responsible for the genesis of PF is still unknown, transforming growth factor beta (TGFbeta1) has been shown to be associated with PF. Angiotensin converting enzyme inhibitors have been shown to prevent the stimulating effect of growth factors. The aim of the present study was to investigate the effect of enalapril on peritoneal function and morphology in a rat model of experimental PF. METHODS: Twenty-one albino Wistar rats were divided into three groups: (1) the control group (C) received 10 mL isotonic saline intraperitoneally (i.p.), (2) the dextrose (Dx) group 10 mL 3.86% dextrose PD solution i.p., and (3) the enalapril-treated group (ENA) 10 cc 3.86% dextrose PD solution i.p. plus 100 mg/L enalapril in drinking water. After 4 weeks, a 1-hour peritoneal equilibration test was performed with 20 mL 2.27% dextrose PD solution. Dialysate-to-plasma urea ratio (D/P urea), glucose reabsorption (D1/D0 glucose), ultrafiltration (UF) volume, and levels of dialysate protein, TGFbeta1, and cancer antigen 125 (CA125) were determined. The parietal peritoneum was evaluated histologically by light microscopy. RESULTS: Administration of enalapril resulted in preserved UF (-0.2 +/- 0.7 mL vs 1.7 +/- 0.3 mL, p < 0.05), protein loss (2.3 +/- 0.5 g/L vs 1.6 +/- 0.2 g/L, p > 0.05), and peritoneal thickness (77 +/- 7 microns vs 38 +/- 5 microns, p < 0.001). D/P urea increased significantly in the Dx group (p< 0.05). Both higher levels of TGFbeta1 (undetectable vs 298 +/- 43 pg/mL, p < 0.001) and lower levels of CA125 in dialysate effluent (0.94 +/- 0.5 U/L vs 0.11 +/- 0.1 U/L, p > 0.05) were determined in the Dx group. CONCLUSION: These findings show that peritoneal morphology and function tests were dramatically deranged in the Dx group. The same properties were partially preserved in the ENA group. The production of TGFbeta1 was significantly reduced but peritoneal thickness was not completely inhibited. In conclusion, by inhibiting the production of TGFbeta1, enalapril can preserve peritoneal histology, peritoneal function, and remodeling of mesothelial cells.


Subject(s)
Angiotensin-Converting Enzyme Inhibitors/pharmacology , Dialysis Solutions/adverse effects , Enalapril/pharmacology , Peritoneal Dialysis, Continuous Ambulatory , Peritoneum/pathology , Animals , Fibrosis , Glucose/adverse effects , Glucose/metabolism , Glucose/pharmacology , Hypertonic Solutions/adverse effects , Male , Peritoneum/drug effects , Peritoneum/metabolism , Proteins/metabolism , Rats , Rats, Wistar , Transforming Growth Factor beta/metabolism , Urea/metabolism
14.
Clin Cancer Res ; 6(12): 4957-64, 2000 Dec.
Article in English | MEDLINE | ID: mdl-11156257

ABSTRACT

We studied the effect of arsenic trioxide (As2O3) on prostate and ovarian carcinoma cell lines. As2O3 has been shown to be effective in leukemia, and acute promyelocytic leukemia in particular, both in vitro and in vivo. As model cell lines, we used DU145 and PC-3 for prostate cancer and MDAH 2774 for ovarian cancer. New modalities of treatment are essential in these kinds of cancers, which produce a high death toll. The 3-(4,5-dimethyl-thiazoyl-2-yl)-2,5-diphenyl-tetrazolium bromide assay was used to evaluate cytotoxicity. Flow cytometric analysis and mono-oligo nucleosome detection-based ELISA were used to determine the apoptosis. Isobologram analysis was used to evaluate synergism and/or the additive effects of As2O3 and conventional chemotherapeutic agents. We clearly demonstrated that As2O3 has significant cytotoxic effect on both prostate and ovarian carcinoma cell lines. The dose range of As2O3 in all three cell lines was approximately 10(-6) M. The mechanism underlying cytotoxicity of As2O3 was shown to be apoptosis. The experiments by butylated hydroxyanisole showed that the cytotoxic effect of As2O3 was not through superoxide generation. There was no synergism, but the additive effects of As2O3 were demonstrated with cisplatin, adriamycin, and etoposide. We strongly suggest that As2O3 alone or in combination with conventional chemotherapeutic agents be evaluated further as a new agent for the treatment of prostate and ovarian cancers.


Subject(s)
Antineoplastic Agents/therapeutic use , Arsenicals/therapeutic use , Ovarian Neoplasms/drug therapy , Oxides/therapeutic use , Prostatic Neoplasms/drug therapy , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Antioxidants/therapeutic use , Apoptosis/drug effects , Arsenic Trioxide , Butylated Hydroxyanisole/metabolism , Carcinogens , Cisplatin/administration & dosage , DNA Fragmentation/drug effects , Dose-Response Relationship, Drug , Doxorubicin/administration & dosage , Enzyme-Linked Immunosorbent Assay , Etoposide/administration & dosage , Female , Flow Cytometry , Humans , Male , Tetrazolium Salts/metabolism , Thiazoles/metabolism , Tumor Cells, Cultured
15.
Leuk Res ; 23(5): 507-12, 1999 May.
Article in English | MEDLINE | ID: mdl-10374865

ABSTRACT

To elucidate the roles of serine/threonine protein phosphatases type 1 (PP1) and type 2A (PP2A) in methylprednisolone-induced differentiation of HL60 cells into granulocytes and K562 cells into monocytes, we examined the effect of serine/threonine protein phosphatase inhibitors, okadaic acid and Cal-A on the proliferation/differentiation of HL60 and K562 cells. Okadaic acid and Cal-A augmented methylprednisolone induced granulocytic differentiation and cell death of HL60 cells and monocytic differentiation and cell death of K562 cells in different dose ranges, respectively. These data suggest an important role of PP1 and PP2A in the mechanism leading to differentiation of leukemic cells.


Subject(s)
Leukemia, Myeloid/drug therapy , Methylprednisolone/therapeutic use , Phosphoprotein Phosphatases/metabolism , Cell Death/drug effects , Cell Differentiation/drug effects , Enzyme Inhibitors/pharmacology , HL-60 Cells , Humans , Leukemia, Myeloid/pathology , Marine Toxins , Okadaic Acid/pharmacology , Oxazoles/pharmacology
16.
Article in English | MEDLINE | ID: mdl-9684193

ABSTRACT

As the first study of its kind in the Aegean region of Turkey, we examined the incidence of sensitivity to Parietaria pollen in patients with allergic rhinitis and/or asthma living in the Mediterranean climate of the Aegean coast. On the Mediterranean, there are characteristic climatic conditions (mild winters, dry summers, etc.) which facilitate the growth of a typical vegetation and the production of allergenic pollen, such as that from Parietaria. These pollen types differ greatly from those of central and northern Europe. We skin tested 132 patients with a clinical history of seasonal rhinitis and/or asthma symptoms. Each patient was skin tested with extracts of grass, weed, tree and cereal pollens, and serum samples were collected for specific IgE assays for Parietaria. Sixty-nine of the 132 patients (52%) showed skin reactivity to Parietaria; seven of these (10%) had monosensitization to Parietaria. Fifty-six out of 69 patients (81%) had specific IgE in their serum to Parietaria pollen. Based on skin test reactions, we concluded that Parietaria is important in terms of clinical symptoms and that it is the most common weed pollen in the Aegean region in Turkey.


Subject(s)
Allergens/immunology , Hypersensitivity/diagnosis , Immunoglobulin E/blood , Pollen/immunology , Adolescent , Adult , Antibody Specificity , Asthma/diagnosis , Asthma/immunology , Biomarkers/blood , Female , Humans , Hypersensitivity/epidemiology , Hypersensitivity/immunology , Male , Middle Aged , Poaceae , Rhinitis, Allergic, Seasonal/diagnosis , Rhinitis, Allergic, Seasonal/immunology , Skin Tests/methods , Turkey/epidemiology
17.
Immunology ; 93(2): 221-9, 1998 Feb.
Article in English | MEDLINE | ID: mdl-9616372

ABSTRACT

Irradiated (800 rads) AKR mice received intravenous (i.v.) reconstitution with a mixture of B10.BR T-depleted bone marrow cells and spleen cells. Only in groups of mice treated additionally with i.v. cyclophosphamide (Cy; 150 mg/kg), 24 hr before transplantation, was long-term (> 60% at 50 days) survival seen. In mice receiving only irradiation all animals died by 30 days post-transplantation. Histological changes consistent with graft-versus-host disease (GVHD) were seen in the liver of reconstituted mice at 30 days, along with an organ-specific increase in V beta 3 T-cell receptor-positive (TCR+) cells. No such increase in V beta 3 TCR+ cells was seen in the spleen from the same mice. These data are consistent with a tissue antigen-driven expansion of V beta 3 TCR+ cells associated with GVHD in the liver in this model. When we analysed cytokine production in vitro from CD3+ cells restimulated with 'host' (AKR) antigen-presenting cells (APC), we found a transition in cytokine production from preferential synthesis of type-1 cytokines [interleukin-2 (IL-2) and interferon-gamma (IFN-gamma)] at early times (day 15) post-reconstitution to increased production of type-2 cytokines [IL-4, transforming growth factor-beta (TGF-beta) and IL-10] at later times (day 30) post-reconstitution in Cy-treated recipients. Animals not receiving Cy did not show this 'switch' in cytokine production at later time points. We have observed a similar polarization in cytokine production, along with increased graft survival, in recipients of vascularized and non-vascularized allografts after portal venous (p.v.), but not i.v., pretransplant donor-specific immunization. We next studied AKR mice receiving 800 rads and subsequently reconstituted with B10.BR stem cells via the p.v. route. Again these mice showed prolonged survival (> 50% at 50 days), with polarization to IL-4, IL-10 and TGF-beta on restimulation of CD3+ cells in vitro at 30 days post-transplant and increased V beta 3 TCR+ cells in the liver. Infusion of anti-IL-12 monoclonal antibodies into irradiated mice receiving i.v. cell reconstitution produced a similar pattern of changes to those seen after p.v. reconstitution, while a combination of anti-IL-10 and anti-TGF-beta monoclonal antibodies reversed the changes seen after p.v. reconstitution. These data are consistent with an important role for differential cytokine production in the regulation of GVHD following allogeneic bone marrow transplantation.


Subject(s)
Bone Marrow Transplantation/immunology , Cytokines/biosynthesis , Receptors, Antigen, T-Cell, alpha-beta/metabolism , T-Lymphocyte Subsets/immunology , Animals , Antibodies, Monoclonal/immunology , Bone Marrow Transplantation/methods , Cyclophosphamide/pharmacology , Cytokines/immunology , Female , Graft Survival/immunology , Graft vs Host Disease/immunology , Immunosuppressive Agents/pharmacology , Liver/immunology , Male , Mice , Mice, Inbred AKR , Mice, Inbred Strains , Portal Vein , Spleen/immunology , Whole-Body Irradiation
18.
Clin Rheumatol ; 17(2): 176-7, 1998.
Article in English | MEDLINE | ID: mdl-9641522

ABSTRACT

In this paper, we describe a 25-year-old white man with Behçet's disease who developed superior vena cava syndrome which was followed with the diagnosis of pseudotumour cerebri based on bilateral papilledema for 6 months. Complete superior vena cava obstruction was detected by magnetic resonance imaging (MRI). Secondary reasons for papilledema were all excluded. Treatment of prednisone, pulse cyclophosphamide and heparin was started and clinical symptoms and fundoscopic changes completely disappeared in 2 weeks. In conclusion, we think that Behcet's disease should always be remembered in the differential diagnosis of unidentified neurological signs especially in regions where the disease is relatively common.


Subject(s)
Behcet Syndrome/complications , Pseudotumor Cerebri/complications , Superior Vena Cava Syndrome/etiology , Thrombosis/complications , Adult , Diagnosis, Differential , Humans , Magnetic Resonance Imaging , Male , Superior Vena Cava Syndrome/diagnosis , Thrombosis/diagnosis
19.
Allergy Asthma Proc ; 19(2): 69-73, 1998.
Article in English | MEDLINE | ID: mdl-9578914

ABSTRACT

We studied serum ECP levels in 21 seasonal allergic patients (16 patients with rhinitis; 5 with rhinitis and asthma) diagnosed by history, skin tests, and RAST. Seventeen healthy subjects were selected as a control group. None of the patients had received medications. Total IgE levels were also measured and correlated with ECP levels. Mean IgE level was found to be higher in patients than controls (p < 0.05). Patients with asthma and rhinitis had higher IgE values than those with rhinitis alone (p < 0.05). Serum ECP levels in the patient group were significantly higher than those in the control group (p < 0.05). No statistically significant difference was found between ECP levels in patients with rhinitis and rhinitis plus asthma groups, although mean ECP was higher level in the later group. Total IgE and ECP levels were correlated positively in the patients (r = 0.630, p < 0.05). We conclude that the extent of allergic inflammation in mucosal surfaces such as allergic rhinitis plus asthma, might influence serum ECP levels.


Subject(s)
Asthma/blood , Blood Proteins/analysis , Immunoglobulin E/blood , Inflammation Mediators/blood , Rhinitis, Allergic, Seasonal/blood , Ribonucleases , Adolescent , Adult , Eosinophil Granule Proteins , Eosinophils , Female , Humans , Male , Middle Aged
20.
Immunology ; 92(1): 20-5, 1997 Sep.
Article in English | MEDLINE | ID: mdl-9370919

ABSTRACT

A number of quantitative and qualitative changes in the pattern of cytokine production have been reported to accompany the process of ageing in laboratory animals and in human populations, including an increase in serum levels of interleukin-1 (IL-1) and IL-6, as well as increased concanavalin A (ConA)-stimulated production of IL-4, IL-10 and transforming growth factor-beta (TGF-beta), and decreased production of IL-2 from cultured spleen cells. Increased IL-1 and IL-6 production is a feature of splenic adherent cells and peritoneal exudate cells taken from aged mice and stimulated with lipopolysaccharide in vitro. We have asked whether the altered production of lymphocyte-derived cytokines (IL-4, IL-2, TGF-beta) is itself a function of a primary alteration in IL-1/IL-6 production (from macrophage/monocytes) by infusing monoclonal antibodies to these cytokines prior to harvesting cells from aged mice and stimulating the cells in vitro. Anti-IL-6, but not anti-IL-1, reversed the age-associated alteration in lymphocyte cytokine production. The general pattern of cytokine production in aged mice is of a type-2 cytokine type, and thus these data are consistent with the idea that increased production of IL-6 in aged animals is causally implicated in this age-associated polarization to type-2 cytokine production.


Subject(s)
Aging/immunology , Cytokines/biosynthesis , Animals , Antibody Specificity , Antigen-Presenting Cells/immunology , Cell Adhesion/immunology , Cell Culture Techniques , Hyaluronan Receptors/analysis , Interleukin-6/immunology , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Mice, Inbred DBA , Spleen/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...